Wednesday
August 6, 2025
4:01 PM ET
Xencor Reports Second Quarter 2025 Financial Results
Wednesday
May 7, 2025
4:01 PM ET
Xencor Reports First Quarter 2025 Financial Results
Tuesday
April 29, 2025
4:01 PM ET
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
Thursday
February 27, 2025
8:01 AM ET
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results